Suppr超能文献

奥沙米特对豚鼠和大鼠中SRS-A及合成白三烯的多种活性的抑制作用。

Inhibitory effects of oxatomide on several activities of SRS-A and synthetic leukotrienes in guinea-pigs and rats.

作者信息

Ohmori K, Ishii H, Kubota T, Shuto K, Nakamizo N

出版信息

Arch Int Pharmacodyn Ther. 1985 May;275(1):139-50.

PMID:2862849
Abstract

Effects of oxatomide, an orally active anti-allergic drug, on several activities of slow reacting substance of anaphylaxis (SRS-A) and synthetic leukotrienes (LT) C4, D4 and E4 were investigated. In addition, such activities of oxatomide were compared with those of FPL-55712. Oxatomide, at a concentration of 3 X 10(-8) M or higher, inhibited the phasic contractions of isolated guinea-pig ileum induced by partially purified SRS-Agp and SRS-Arat which were anaphylactically generated from guinea-pig lung fragments and rat peritoneal cavities, respectively. The 50% inhibitory concentrations (IC 50) of oxatomide to the contractions by SRS-Agp and SRS-Arat are 2.7 +/- 0.9 X 10(-7) M and 1.6 +/- 0.3 X 10(-7) M, respectively. Oxatomide also inhibited the LTC4, LTD4, histamine or serotonin-induced contractions of ileum. FPL-55712, a specific SRS-A antagonist, inhibited SRS-Agp, SRS-Arat, LTC4 or LTD4-induced contractions at concentrations ranging from 10(-9) M to 10(-6) M without affecting histamine and serotonin responses. Oxatomide produced dose-dependent relaxations of isolated guinea-pig tracheal and lung parenchymal strips precontracted with LTD4 and histamine. Oxatomide, at doses 10 and 30 mg/kg (p.o.), inhibited significantly the increase in vascular permeability produced by LTC4, LTE4, histamine and serotonin in rats. These results suggest that, although less effective and less selective as compared with FPL-55712, oxatomide exerts inhibitory effects on SRS-A activities, and that such effects could partly explain the anti-allergic effects of the compound.

摘要

研究了口服活性抗过敏药物奥沙米特对过敏反应慢反应物质(SRS-A)以及合成白三烯(LT)C4、D4和E4多种活性的影响。此外,还将奥沙米特的这些活性与FPL-55712的活性进行了比较。奥沙米特浓度为3×10⁻⁸M或更高时,可抑制分别由豚鼠肺组织碎片和大鼠腹腔过敏性产生的部分纯化SRS-Agp和SRS-Arat诱导的离体豚鼠回肠的相性收缩。奥沙米特对SRS-Agp和SRS-Arat收缩的50%抑制浓度(IC₅₀)分别为2.7±0.9×10⁻⁷M和1.6±0.3×10⁻⁷M。奥沙米特还可抑制LTC4、LTD4、组胺或5-羟色胺诱导的回肠收缩。特异性SRS-A拮抗剂FPL-55712在10⁻⁹M至10⁻⁶M浓度范围内可抑制SRS-Agp、SRS-Arat、LTC4或LTD4诱导的收缩,而不影响组胺和5-羟色胺反应。奥沙米特可使预先用LTD4和组胺预收缩的离体豚鼠气管和肺实质条产生剂量依赖性舒张。奥沙米特口服剂量为10和30mg/kg时,可显著抑制LTC4、LTE4、组胺和5-羟色胺在大鼠中引起的血管通透性增加。这些结果表明,尽管与FPL-55712相比效果较差且选择性较低,但奥沙米特对SRS-A活性具有抑制作用,且这种作用可部分解释该化合物的抗过敏作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验